EUVIMEDEUVIMED entdecken
Crossref

Combined treatment with teneligliptin and canagliflozin additively suppresses high-fat diet-induced body weight gain in mice with modulation of lipid metabolism-related gene expression

Satoko Kawarasaki, Honami Sawazaki, Hiroaki Iijima, Haruya Takahashi, Wataru Nomura, Kazuo Inoue, Teruo Kawada, Tsuyoshi Goto

European Journal of Pharmacology · 2023

DOI: 10.1016/j.ejphar.2023.175682 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmacology, 2023. Verfasst von Satoko Kawarasaki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Function of Food, Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Uji, 611-0011…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Dipeptidyl-Peptidase IV Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Mitsubishi Tanabe Pharma Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the treatment of type 2 diabetes mellitus (T2DM), comprehensive management of multiple risk factors, such as blood glucose, body weight, and lipids, is important to prevent disease progression. Although the combination of dipeptidyl peptidase-4 (DPP-4) inhibitor and sodium-glucose co-transporter 2 (SGLT2) inhibitor is often used clinically, the effects of this combination, other than glucose metabolism, have yet to be thoroughly investigated. In this study, we evaluated the effects of combined treatment with a DPP-4 inhibitor, teneligliptin, and an SGLT2 inhibitor, canagliflozin, on the body weight and lipid metabolism in high-fat diet (HFD)-induced obese mice. We found that monotherapy with teneligliptin or canagliflozin showed suppressive effects on high-fat diet-induced body weight gain and reduced inguinal white adipose tissue (iWAT) mass, and combined treatment additively reduced body weight gain and iWAT mass. Teneligliptin significantly increased oxygen consumption during the light phase, and this effect was preserved in the combined treatment. The combined treatment did not alter the mRNA expression levels of thermogenesis-related genes in adipose tissue but showed the tendency to additively induce mRNA of fatty acid oxidation-related genes in brown adipose tissue and tended to additively decrease mRNA of fatty acid synthesis-related genes in iWAT and liver tissues. These results suggest that combined treatment with teneligliptin and canagliflozin additively suppresses HFD-induced body weight gain with increasing oxygen consumption and modulating the expression of lipid metabolism-related genes. This combination therapy may provide effective body weight management for patients with T2DM and obesity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsMiceAnimalsCanagliflozinLipid MetabolismDiet, High-FatHypoglycemic AgentsWeight GainBody WeightRNA, MessengerFatty AcidsGene ExpressionPyrazolesThiazolidines

Stichwörter der Autor:innen

CanagliflozinCombined treatmentLipid metabolismTeneligliptin

Substanzen

CanagliflozinSodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsDipeptidyl-Peptidase IV InhibitorsRNA, MessengerFatty Acids3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidinePyrazolesThiazolidines

Autor:innen und Institutionen

  • Laboratory of Molecular Function of Food, Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Uji, 611-0011, Japan.
  • Medical Affairs Department, Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
  • Laboratory of Molecular Function of Food, Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Uji, 611-0011, Japan; Research Unit for Physiological Chemistry, The Center for the…

Förderung

  • Japan Society for the Promotion of Science
  • Mitsubishi Tanabe Pharma Corporation

Zitieren

APA

Kawarasaki, S., Sawazaki, H., Iijima, H., Takahashi, H., Nomura, W., Inoue, K., Kawada, T., & Goto, T. (2023). Combined treatment with teneligliptin and canagliflozin additively suppresses high-fat diet-induced body weight gain in mice with modulation of lipid metabolism-related gene expression. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2023.175682

Vancouver

Kawarasaki S, Sawazaki H, Iijima H, Takahashi H, Nomura W, Inoue K, et al. Combined treatment with teneligliptin and canagliflozin additively suppresses high-fat diet-induced body weight gain in mice with modulation of lipid metabolism-related gene expression. European Journal of Pharmacology. 2023. doi:10.1016/j.ejphar.2023.175682

BibTeX
@article{Kawarasaki2023,
  author = {Kawarasaki, Satoko and Sawazaki, Honami and Iijima, Hiroaki and Takahashi, Haruya and Nomura, Wataru and Inoue, Kazuo and Kawada, Teruo and Goto, Tsuyoshi},
  title = {Combined treatment with teneligliptin and canagliflozin additively suppresses high-fat diet-induced body weight gain in mice with modulation of lipid metabolism-related gene expression},
  journal = {European Journal of Pharmacology},
  year = {2023},
  doi = {10.1016/j.ejphar.2023.175682}
}
Kostenlos starten →